SEAMLESS SPECIALTY PHARMA SERVICES Mawdsleys Specialty Pharma offers Global Named Patient Programmes Medical Affairs & Pharmacovigilance Distribution and logistics aligned with GDP Full product registration and regulatory affairs support to license and commercialise products in Brazil, Israel and the UK In country Marketing and Sales teams specialising in rare disease, speciality pharma, oncology, haematology, critical care and orphan products Global Named Patient Programmes A Named Patient Programme (NPP) provides a safe, legal and ethical route for physicians and patients to access medications that have not yet been licensed or made commercially available in their home country. It is also often called an Early Access Programme. Examples of why patients may not have a licensed treatment option include when a medicine is new and has not yet been approved in their country because a clinical trial in which they have been enrolled is finishing, or because a previously licensed medicine has been discontinued. Mawdsleys Specialty Pharma has a track record of successfully launching such programmes by partnering with small and mid-size companies to advise them on suitable programme design, regulatory compliance and successful implementation. In all these cases, Mawdsleys can provide a bespoke, turnkey solution which will provide patients with quick and ethical access to the medicines they need. By centralising access for patients through Mawdsleys, the pharmaceutical company will gain visibility of demand, as well as control of the information which passes to and from the healthcare provider. This access will be fully controlled by Mawdsleys in accordance with the particular commercial and clinical parameters agreed with the pharmaceutical company. Managed Access Compassionate Supply Expanded Access Early Access Why launch a Named Patient Programme? Helps to satisfy unmet patient needs in a local territory Increases company/product awareness in a local territory Establishes & enhances KOL (Key Opinion Leaders) networks and Patient Advocacy Groups Commercial insight to aid in launch decision Captures pharmacovigilance data while complying with regulations Gather physician feedback on, for example, ease of use Product Licensing For pharmaceutical companies who want to get their products licensed in new territories, Mawdsleys Specialty Pharma has the expertise to manage this process on your behalf. Using the skills and extensive experience within the Mawdsleys Group, we can manage submissions to regulatory bodies on behalf of pharmaceutical companies, navigating the process to ensure a smooth pathway to commercialisation. Mawdsleys Specialty Pharma is dedicated to seeking breakthrough medical innovations for the healthcare community through in-licensing and long term partnerships with small and mid-size specialty pharmaceutical companies. We are particularly focused on high added value products that require a well-established partner with a track record of success stories. Find out more about the licensing service Mawdsleys provides: Prelaunch Rapid Registration & Reimbursement License / Commercialise Our Location Salford – International House International House 4 Houston Park, Montford Street Salford M50 2RP +44 (0) 161 742 3482 info@mawdsleys.com Contact us Contact us First Name* Last Name* Email* Company Enquiry CAPTCHA What goes up must come:* COMPANY About Us Latest News SERVICES Secondary Care Services Pre Wholesale Services Pharmaceutical Logistics Pharma Services POLICIES & LEGAL STATEMENTS Privacy Policy Cookie Policy Gender Pay Gap Info Modern Slavery Act Statement Mawdsleys Brooks Retirement Benefit Scheme Tax Strategy Section 172 (1) Statement CONTACT Number 3 South Langworthy Road Salford M50 2PW Mawdsleys Online 3PL Client Portal Login © Mawdsley-Brooks & Co. Ltd. Registered in the England, No. 44701. Sitemap Website & SEO by Tetraza Digital Ltd